NO20070377L - Progesteron reseptor antagonist befruktningshindrende regimer og sett. - Google Patents

Progesteron reseptor antagonist befruktningshindrende regimer og sett.

Info

Publication number
NO20070377L
NO20070377L NO20070377A NO20070377A NO20070377L NO 20070377 L NO20070377 L NO 20070377L NO 20070377 A NO20070377 A NO 20070377A NO 20070377 A NO20070377 A NO 20070377A NO 20070377 L NO20070377 L NO 20070377L
Authority
NO
Norway
Prior art keywords
sets
receptor antagonist
progesterone receptor
fertilization
regimens
Prior art date
Application number
NO20070377A
Other languages
English (en)
Inventor
Andrew Fensome
Gary Grubb
Casey Cameron Mccomas
Ginger Dale Constantine
Edward George Melenski
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070377(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070377L publication Critical patent/NO20070377L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En metode for prevensjon er gitt som involverer levering av 21 til 27 påfølgende dager av én eller flere PR antagonister i fravær av en progestin, østrogen eller annen steroid forbindelse, fulgt av 1 til 7 dager uten noe aktivt middel. Også beskrevet er et farmasøytisk anvendelig sett for å lette levering av dette regimet.
NO20070377A 2004-07-07 2007-01-19 Progesteron reseptor antagonist befruktningshindrende regimer og sett. NO20070377L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29
PCT/US2005/023798 WO2006017075A1 (en) 2004-07-07 2005-07-06 Progesterone receptor antagonist contraceptive regimens and kits

Publications (1)

Publication Number Publication Date
NO20070377L true NO20070377L (no) 2007-02-07

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070377A NO20070377L (no) 2004-07-07 2007-01-19 Progesteron reseptor antagonist befruktningshindrende regimer og sett.

Country Status (20)

Country Link
US (1) US20060009509A1 (no)
EP (1) EP1773323A1 (no)
JP (1) JP2008505906A (no)
KR (1) KR20070039912A (no)
AR (1) AR049664A1 (no)
AU (1) AU2005271974A1 (no)
BR (1) BRPI0512993A (no)
CA (1) CA2571198A1 (no)
CR (1) CR8800A (no)
EC (1) ECSP077131A (no)
GT (1) GT200500186A (no)
IL (1) IL180238A0 (no)
MX (1) MXPA06014580A (no)
NO (1) NO20070377L (no)
PA (1) PA8638501A1 (no)
PE (1) PE20060485A1 (no)
RU (1) RU2006144069A (no)
SV (1) SV2006002166A (no)
TW (1) TW200605880A (no)
WO (1) WO2006017075A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
ATE497745T1 (de) 2004-07-09 2011-02-15 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
NZ592275A (en) 2008-10-17 2013-04-26 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2757496A1 (en) 2009-04-14 2010-10-21 Andre Ulmann Method for on-demand contraception
SG176288A1 (en) 2009-06-18 2012-01-30 Pfizer Bicyclic and tricyclic compounds as kat ii inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
CN103228660A (zh) 2010-12-01 2013-07-31 辉瑞大药厂 Kat ii 抑制剂
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9522154B2 (en) 2013-03-14 2016-12-20 Laboratoire Hra-Pharma Method for scheduling ovulation
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
BRPI0512993A (pt) 2008-04-22
IL180238A0 (en) 2007-07-04
EP1773323A1 (en) 2007-04-18
KR20070039912A (ko) 2007-04-13
AR049664A1 (es) 2006-08-23
US20060009509A1 (en) 2006-01-12
JP2008505906A (ja) 2008-02-28
TW200605880A (en) 2006-02-16
GT200500186A (es) 2006-03-02
SV2006002166A (es) 2006-05-09
ECSP077131A (es) 2007-02-28
WO2006017075A1 (en) 2006-02-16
MXPA06014580A (es) 2007-03-23
RU2006144069A (ru) 2008-08-20
CA2571198A1 (en) 2006-02-16
PE20060485A1 (es) 2006-06-24
PA8638501A1 (es) 2006-07-03
CR8800A (es) 2007-08-28
AU2005271974A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20070377L (no) Progesteron reseptor antagonist befruktningshindrende regimer og sett.
TW200603813A (en) Cyclic progestin regimens and kits
NO341685B1 (no) Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
RS20070075A (en) 15beta-substituted steroids having selective estrogenic activity
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
CY1118236T1 (el) Μεθοδος για αντισυλληψη κατ' απαιτηση
DE602005026290D1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
NO20091190L (no) Fremgangsmater og sammensetninger for behandling av kreft
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
NO20045217L (no) Anvendelse av tio-oxindolderivater for behandling av hormon relaterte tilstander
Milionis et al. Progesterone in gender-affirming therapy of trans women
WO2005011617A3 (en) Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
Genazzani et al. Drospirenone and its antialdosterone properties
CA2459033A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
ATE500834T1 (de) Kontrazeptivum
DE602004018921D1 (de) D dienogest
WO2008109719A3 (en) Steroids derivatives as selective progesterone receptor modulators
BR0315746A (pt) Redução estereospecìfica de sapogen-3-onas
WO2009140225A3 (en) Anti-inflammatory and immunosuppresive glucocorticoid steroids
NO20091057L (no) Oral legemiddelform for prevensjon
权红梅 The Main Social Variants in the English Language
李树红 et al. Some Strategies for Teaching English to Beginning Students: a Description of a Class

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application